Citadel Advisors’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-148,841
| Closed | -$2.6M | – | 14055 |
|
|
2020
Q4 | $2.6M | Buy |
148,841
+2,420
| +2% | +$33.9K | ﹤0.01% | 4824 |
|
|
2020
Q3 | $1.71M | Sell |
146,421
-12,043
| -8% | -$160K | ﹤0.01% | 5023 |
|
|
2020
Q2 | $2.06M | Buy |
158,464
+52,129
| +49% | +$626K | ﹤0.01% | 4527 |
|
|
2020
Q1 | $985K | Sell |
106,335
-31,250
| -23% | -$437K | ﹤0.01% | 5363 |
|
|
2019
Q4 | $2.28M | Sell |
137,585
-10,888
| -7% | -$177K | ﹤0.01% | 4193 |
|
|
2019
Q3 | $2.47M | Sell |
148,473
-177,831
| -54% | -$2.46M | ﹤0.01% | 4143 |
|
|
2019
Q2 | $4.49M | Buy |
326,304
+238,001
| +270% | +$3.64M | ﹤0.01% | 3255 |
|
|
2019
Q1 | $1.52M | Buy |
88,303
+31,894
| +57% | +$505K | ﹤0.01% | 4898 |
|
|
2018
Q4 | $721K | Sell |
56,409
-28,280
| -33% | -$429K | ﹤0.01% | 5817 |
|
|
2018
Q3 | $1.38M | Buy |
84,689
+4,911
| +6% | +$70.2K | ﹤0.01% | 5009 |
|
|
2018
Q2 | $1.03M | Buy |
+79,778
| New | +$1.08M | ﹤0.01% | 5165 |
|
|
2017
Q1 | – | Sell |
-14,375
| Closed | -$215K | – | 8262 |
|
|
2016
Q4 | $215K | Buy |
+14,375
| New | +$202K | ﹤0.01% | 6208 |
|
|
2016
Q1 | – | Sell |
-8,702
| Closed | -$100K | – | 8467 |
|
|
2015
Q4 | $100K | Buy |
+8,702
| New | +$108K | ﹤0.01% | 6693 |
|
|
2015
Q3 | – | Sell |
-1,442
| Closed | -$20K | – | 9391 |
|
|
2015
Q2 | $20K | Buy |
+1,442
| New | +$19.5K | ﹤0.01% | 8161 |
|
Citadel Advisors's OXFD Position: Q1 2021 in Review
Citadel Advisors sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 148,841 shares — an estimated $2.6M sold.
Citadel Advisors first reported a position in OXFD in Q2 2015 and held it in 14 quarters. The position peaked at $4.49M in Q2 2019. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Citadel Advisors reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
- Citadel Advisors sold 148,841 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $2.6M.
- Citadel Advisors first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q2 2015 and held it in 14 quarters.
- Citadel Advisors's Oxford Immunotec Global PLC Ordinary Shares position peaked at $4.49M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.
Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.